Clinical Trial Update: TACE for HCC by TANDEM and Idarubicin

View source ↗

Summary

A clinical trial evaluating transarterial chemoembolization for hepatocellular carcinoma using the TANDEM approach with idarubicin has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Idarubicin (idarubicin)
• TANDEM

Snippet

Sponsor: University Hospital, Montpellier | Conditions: Hepatocellular Carcinoma (HCC) | Status: COMPLETED